Your browser doesn't support javascript.
loading
Immunogenicity and protective efficacy of nanoparticle formulations of L-SseB against Salmonella infection.
Das, Sayan; Howlader, Debaki R; Lu, Ti; Whittier, Sean K; Hu, Gang; Sharma, Simran; Dietz, Zackary K; Ratnakaram, Siva S K; Varisco, David J; Ernst, Robert K; Picking, William D; Picking, Wendy L.
Affiliation
  • Das S; Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, United States.
  • Howlader DR; Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, United States.
  • Lu T; Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, United States.
  • Whittier SK; Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, United States.
  • Hu G; Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, United States.
  • Sharma S; Department of Veterinary Pathobiology and Bond Life Science Center, University of Missouri, Columbia, MO, United States.
  • Dietz ZK; Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, United States.
  • Ratnakaram SSK; Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, United States.
  • Varisco DJ; Department of Microbial Pathogenesis, University of Maryland, Baltimore, MD, United States.
  • Ernst RK; Department of Microbial Pathogenesis, University of Maryland, Baltimore, MD, United States.
  • Picking WD; Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, United States.
  • Picking WL; Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, United States.
Front Immunol ; 14: 1208848, 2023.
Article in En | MEDLINE | ID: mdl-37457702
ABSTRACT
Salmonella enterica, a Gram-negative pathogen, has over 2500 serovars that infect a wide range of hosts. In humans, S. enterica causes typhoid or gastroenteritis and is a major public health concern. In this study, SseB (the tip protein of the Salmonella pathogenicity island 2 type III secretion system) was fused with the LTA1 subunit of labile-toxin from enterotoxigenic E. coli to make the self-adjuvanting antigen L-SseB. Two unique nanoparticle formulations were developed to allow multimeric presentation of L-SseB. Mice were vaccinated with these formulations and protective efficacy determined via challenging the mice with S. enterica serovars. The polysaccharide (chitosan) formulation was found to elicit better protection when compared to the squalene nanoemulsion. When the polysaccharide formulation was used to vaccinate rabbits, protection from S. enterica challenge was elicited. In summary, L-SseB in a particulate polysaccharide formulation appears to be an attractive candidate vaccine capable of broad protection against S. enterica.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Salmonella Infections / Typhoid Fever / Typhoid-Paratyphoid Vaccines / Salmonella enterica Limits: Animals / Humans Language: En Journal: Front Immunol Year: 2023 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Salmonella Infections / Typhoid Fever / Typhoid-Paratyphoid Vaccines / Salmonella enterica Limits: Animals / Humans Language: En Journal: Front Immunol Year: 2023 Document type: Article Affiliation country: